defactinib (VS-6063)

DRUG2 trials

Sponsors

Verastem, Inc.

Conditions

Lung CancerMalignant Pleural MesotheliomaNon Small Cell Lung Cancer

Phase 2

Placebo Controlled Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma

TerminatedNCT01870609

Verastem, Inc.Malignant Pleural Mesothelioma

Start: 2013-09-30End: 2016-01-31Updated: 2017-01-30

Phase II Study of VS-6063 in Patients With KRAS Mutant Non-Small Cell Lung Cancer

CompletedNCT01951690

Verastem, Inc.Lung Cancer, Non Small Cell Lung Cancer

Start: 2013-09-30End: 2016-06-30Updated: 2017-04-13

Related Papers

Abstract 4236: FAK inhibitor VS-6063 (defactinib) targets mesothelioma cancer stem cells, which are enriched by standard of care chemotherapy

Cancer Research2015-08-017 citations

COMMAND: A phase II randomized, double-blind, placebo-controlled, multicenter study of defactinib as maintenance therapy in subjects with malignant pleural mesothelioma that has not progressed on at least four cycles of pemetrexed/platinum therapy.

Journal of Clinical Oncology2014-05-205 citations